Key Highlights

  • Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) traded 290.33% higher after retiring all Series C preferred stock for USD 1,270,970, a nano-cap move on about 45 times normal volume.
  • Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) gained 29.68% on 44% Revenue growth to USD 107.2 million, and raised 2026 guidance plus a 2030 outlook above USD 1 billion.
  • ADMA Biologics, Inc. (NASDAQ:ADMA) climbed 25.52% and Vericel rose 20.27%, both on higher profit or guidance following third-quarter results.
  • Precision BioSciences (NASDAQ:DTIL) rose 17.49% to about USD 9.54 even after pricing an offering of about USD 125 million at USD 7.75 per share.

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT): Tidying the Capital Structure

The largest healthcare gain is at Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT), which was quoted at USD 0.7471 in trading on November 5, 2026, according to published market data, up 290.33% from about USD 0.19. The clinical-stage company develops Bisphosphocin antimicrobials aimed at infections such as MRSA and VRE. At 8:02 a.m. ET it announced that it had redeemed all 127,097 Series C Convertible Preferred Shares for USD 1,270,970 in cash under an agreement dated November 2, 2026. Convertible preferred can be exchanged into common shares, often at a discount, so each conversion adds shares and can push a low-priced stock lower. Chief Executive Kelvin Cooper said retiring the series simplifies the Capital Structure and removes the potential for further dilution. The price is cash: the release warns that runway may shrink, and the company has not reported meaningful revenue. With a float near 1.4 million shares in published coverage and Volume of about 351 million shares, a handful of trades can move the price and quoted moves can reverse.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): Commercial Momentum Pays Off

The 29.68% gain at Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), to USD 13.57, followed third-quarter results released November 5, 2026 and is the clearest case of commercial execution in the group. Revenue climbed 44% to USD 107.2 million, Recorlev, a Cushing's syndrome treatment, rose 93% to USD 71.5 million, and Net Income was USD 11.3 million against USD 0.6 million. 2026 revenue guidance went up to USD 395 million to USD 405 million, and the 2030 outlook now tops USD 1 billion, up from about USD 750 million. Gvoke fell 14% to USD 21.7 million, partly due to a one-time gross-to-net adjustment of about USD 4 million, a revision to rebates and discounts. Recorlev made up about two-thirds of revenue on simple arithmetic. Nine-month results still show a net loss of USD 17.6 million because of a one-time non-cash charge linked to the 2028 convertible notes exchange. Debt of USD 189.7 million against cash of USD 131.1 million is the main Balance Sheet risk, and a rally this size can give back gains.

ADMA Biologics, Inc. (NASDAQ:ADMA): Product Mix and Share Repurchases

The 25.52% rally at ADMA Biologics, Inc. (NASDAQ:ADMA), to USD 13.16, followed results released November 4, 2026. Revenue came in at USD 141.1 million, up 5%, yet GAAP net income jumped 37% to USD 49.9 million, because ASCENIV, its immune globulin for primary immunodeficiency, grew 31% to USD 124.7 million while older BIVIGAM fell 35%. Adjusted EBITDA rose 32% to USD 77.3 million, and the company lifted its adjusted profit guidance to at least USD 180 million for net income and USD 275 million for EBITDA, though the size of the lift cannot be checked against earlier minimums. Year to date the company has repurchased 16.5 million shares, about 6.3% of shares outstanding at the end of 2025, and it is on track for repurchases of USD 200 million or more in 2026. Borrowing has partly funded that effort, with debt near USD 195.9 million on simple arithmetic versus roughly USD 72.1 million at the end of 2025. Reliance on ASCENIV, a competitive immune globulin market and plasma Supply are the main risks, and gains of this size can give back ground.

Vericel Corporation (NASDAQ:VCEL): Cartilage and Burn Care Both Advance

Shares of Vericel Corporation (NASDAQ:VCEL) rose 20.27% to USD 54.70 after third-quarter results on November 5, 2026. Total net revenue grew 26% to USD 85.4 million, MACI, the cartilage repair therapy, contributed USD 67.4 million, and Burn Care revenue climbed 52% to USD 18.0 million. The company noted its highest quarterly MACI Arthro case count since launch. Net income rose 179% to USD 14.2 million and adjusted EBITDA of USD 25.2 million lifted the Margin to 30%, the Operating Leverage typical of a specialty Biologics Business with mostly fixed costs. Full-year revenue guidance went up to USD 344 million to USD 346 million from USD 330 million to USD 340 million, and cash stood at USD 235.6 million with no debt. The limit is valuation: published market data implies a multiple near 118 on trailing earnings, so a miss would be costly. MACI accounted for about four-fifths of revenue on simple arithmetic, and the timing or reimbursement of BARDA contract revenue for NexoBrid can move quarters. Volume was below average, so the quoted gain can partly reverse.

Precision BioSciences (NASDAQ:DTIL): A Share Sale That Did Not Halt the Advance

Precision BioSciences (NASDAQ:DTIL) rose 17.49% to about USD 9.54 on volume of 5.79 times normal, the same day it priced an underwritten offering of about USD 125 million at USD 7.75 per share. The deal covers 10,235,077 common shares plus pre-funded warrants for up to 5,893,964 shares, with TD Cowen and Guggenheim Securities as joint book-running managers, and closing is expected on or about November 6, 2026. Proceeds are earmarked for PBGENE-HBV and PBGENE-DMD, its hepatitis B and Duchenne muscular dystrophy gene-editing programs, along with general corporate purposes. A pre-funded Warrant lets an investor pay nearly the full price up front and exercise later for a nominal sum. Simple arithmetic puts the new securities at roughly 16.1 million shares, close to half of the USD 266.51 million Market Value in published market data, so dilution is material. The company did not explain why the stock rose despite the raise. Gene editing carries trial, safety and regulatory risks, and a quoted intraday gain can reverse.

Where Things Stand

These healthcare gains rest on different foundations. The evidence suggests the strongest are those with reported commercial results, while the nano-cap spike rests on a balance-sheet cleanup in a tiny float. Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), ADMA and Vericel reported higher profit and raised or lifted guidance, with debt, concentration and valuation as counterweights. Precision BioSciences (NASDAQ:DTIL) rose despite diluting holders, which shows how funding certainty can outweigh dilution in the short run. Quoted gains can reverse, and nothing here implies they will last. The next catalysts are the closing of the Precision offering, fourth-quarter reports and any new financing at Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT).